SAN FRANCISCO, June 11, 2021 /PRNewswire/ -- Invitae (NYSE:
NVTA), a leading medical genetics company, today announced the
appointment of Roxi Wen as its chief
financial officer, effective June 21,
2021. Wen brings decades of success as a senior financial
executive where she scaled global technology and medical technology
companies.
"We're delighted Roxi will be joining our team. Her track record
of driving growth, financial management and execution of unique
business models in the U.S. and international markets across
technology and life science settings is well suited to our goals,"
said Sean George, Ph.D., co-founder
and chief executive officer of Invitae. "In addition to her
expertise, Roxi shares our team's passion to deliver genetic
information improving healthcare for patients worldwide."
Wen comes to Invitae from Mozilla Corporation, where she served
as CFO for the past two years, leading a transformation covering
all aspects of the business, driving capital allocation, building
analytics capability, restoring profitability and leading revenue
diversification. In that role, she oversaw finance and accounting,
M&A, business development, data and analytics, IT and
engineering operations, workplace resources, and sustainability.
Prior to Mozilla, Wen served in CFO roles at Elo Touch Solutions, a
global innovator and leader in touch screen systems, and General
Electric Critical Power following experience driving capital market
and business finance efforts at Medtronic, a leading medical
technology company. Roxi is a CFA charterholder and has a MBA from
the University of Minnesota.
As previously announced, Shelly D.
Guyer, Invitae's current chief financial officer, will now
focus full-time on the company's Environment, Social and Governance
(ESG) efforts, which were detailed in the publication of Invitae's
first-ever ESG Annual Report in March
2021.
"Shelly has been instrumental in Invitae's growth as she led us
through a tenfold increase in revenue, from a company valuation of
$400 million to over $6 billion, while raising over $3 billion of capital in the process to fuel our
ability to achieve our most important marker of success: growing
from helping tens of thousands of patients to over 2 million as of
a few weeks ago," said Dr. George. "With Roxi's arrival, Shelly
will now shift to focus exclusively on leading our ESG efforts, a
central priority for Invitae, our team, our customers and our
investors. She has long been interested in amplifying our ESG
efforts, and I'm pleased this important effort is in her capable
hands."
About Invitae
Invitae Corporation (NYSE: NVTA) is a leading medical
genetics company whose mission is to bring comprehensive genetic
information into mainstream medicine to improve healthcare for
billions of people. Invitae's goal is to aggregate the world's
genetic tests into a single service with higher quality, faster
turnaround time, and lower prices. For more information, visit the
company's website at invitae.com.
Safe Harbor Statement
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements relating to the appointment of
Roxi Wen as the company's new chief
financial officer and Shelly Guyer's
focus on leading the company's ESG efforts. Forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially, and reported results should
not be considered as an indication of future performance. These
risks and uncertainties include, but are not limited to: the
company's history of losses; the company's ability to compete; the
company's failure to manage growth effectively; the company's need
to scale its infrastructure in advance of demand for its tests and
to increase demand for its tests; the company's ability to use
rapidly changing genetic data to interpret test results accurately
and consistently; security breaches, loss of data and other
disruptions; laws and regulations applicable to the company's
business; and the other risks set forth in the company's filings
with the Securities and Exchange Commission, including the risks
set forth in the company's Quarterly Report on Form 10-Q for the
quarter ended March 31, 2021. These
forward-looking statements speak only as of the date hereof, and
Invitae Corporation disclaims any obligation to update these
forward-looking statements.
Contact for Invitae:
Laura
D'Angelo
ir@invitae.com
(628) 213-3369
View original content to download
multimedia:http://www.prnewswire.com/news-releases/invitae-appoints-technology-and-medtech-veteran-roxi-wen-as-chief-financial-officer-301310689.html
SOURCE Invitae Corporation